Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
This article was originally published in The Pink Sheet Daily
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.
You may also be interested in...
A year after its failed takeover bid for AstraZeneca, Pfizer Inc. continues to face questions about whether it will pursue another large-scale merger, and how it is preparing for a potential spin off.
Pfizer CEO Ian Read voiced his opinions on some of industry’s hottest topics – everything from the pricing of Sovaldi to M&A to the latest innovations, like gene therapy – during a far-ranging discussion at the BIO CEO & Investor conference Feb. 10.
Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.